Literatura académica sobre el tema "DIABETIC NEUROPATHIC PAIN"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "DIABETIC NEUROPATHIC PAIN".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "DIABETIC NEUROPATHIC PAIN"
Rachmantoko, Reza, Zamroni Afif, Dessika Rahmawati, Rodhiyan Rakhmatiar y Shahdevi Nandar Kurniawan. "DIABETIC NEUROPATHIC PAIN". JPHV (Journal of Pain, Vertigo and Headache) 2, n.º 1 (1 de marzo de 2021): 8–12. http://dx.doi.org/10.21776/ub.jphv.2021.002.01.3.
Texto completoPebrianti, Sandra, Bambang Aditya Nugraha y Iwan Shalahuddin. "Manajemen nyeri neuropati pada pasien diabetes melitus tipe 2: Studi literatur". Holistik Jurnal Kesehatan 14, n.º 2 (27 de julio de 2020): 276–82. http://dx.doi.org/10.33024/hjk.v14i2.2828.
Texto completoDi Stefano, Giulia, Andrea Di Lionardo, Giuseppe Di Pietro y Andrea Truini. "Neuropathic Pain Related to Peripheral Neuropathies According to the IASP Grading System Criteria". Brain Sciences 11, n.º 1 (22 de diciembre de 2020): 1. http://dx.doi.org/10.3390/brainsci11010001.
Texto completoKluša, Vija, Juris Rumaks y Ñina Karajeva. "Neuromidin Attenuates Neuropathic Pain in the Streptozocin-Induced Diabetes Model in Rats". Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. 62, n.º 3 (1 de enero de 2008): 85–90. http://dx.doi.org/10.2478/v10046-008-0024-z.
Texto completoMokhtar, Nazarine, Stephane Doly y Christine Courteix. "Diabetic Neuropathic Pain and Serotonin: What Is New in the Last 15 Years?" Biomedicines 11, n.º 7 (6 de julio de 2023): 1924. http://dx.doi.org/10.3390/biomedicines11071924.
Texto completoLi, Hao, Shulin Liu, Zheng Wang, Yonglai Zhang y Kaiguo Wang. "Hydrogen sulfide attenuates diabetic neuropathic pain through NO/cGMP/PKG pathway and μ-opioid receptor". Experimental Biology and Medicine 245, n.º 9 (8 de abril de 2020): 823–34. http://dx.doi.org/10.1177/1535370220918193.
Texto completoShabbir, Syed H. "Psychiatric Underpinnings of Chronic Diabetic Neuropathic Pain". Einstein Journal of Biology and Medicine 30, n.º 1&2 (2 de marzo de 2016): 37. http://dx.doi.org/10.23861/ejbm201530639.
Texto completoZakin, Elina, Rory Abrams y David M. Simpson. "Diabetic Neuropathy". Seminars in Neurology 39, n.º 05 (octubre de 2019): 560–69. http://dx.doi.org/10.1055/s-0039-1688978.
Texto completoSchifilliti, Chiara, Lelio Cucinotta, Viviana Fedele, Carmela Ingegnosi, Salvatore Luca y Carmelo Leotta. "Micronized Palmitoylethanolamide Reduces the Symptoms of Neuropathic Pain in Diabetic Patients". Pain Research and Treatment 2014 (2 de abril de 2014): 1–5. http://dx.doi.org/10.1155/2014/849623.
Texto completoEkinci, Bilge, Bahadir Suleyman, Renad Mammadov, Arzu Gezer, Ali Mendil, Nergis Akbas, Seval Bulut, Cagatay Dal y Halis Suleyman. "The effect of carvacrol upon experımentally ınduced dıabetıc neuropathy and neuropathıc paın ın rats". Acta Poloniae Pharmaceutica - Drug Research 79, n.º 5 (20 de enero de 2023): 707–15. http://dx.doi.org/10.32383/appdr/155354.
Texto completoTesis sobre el tema "DIABETIC NEUROPATHIC PAIN"
Murai, Nobuhito. "Studies on the analgesic effect of (+)-indeloxazine on neuropathic pain". Kyoto University, 2014. http://hdl.handle.net/2433/193548.
Texto completoCAZZATO, Daniele. "Clinical and genetic characterization of neuropathic pain through the model of small fiber neuropathy: implication for diabetic neuropathy". Doctoral thesis, Università degli studi di Ferrara, 2020. http://hdl.handle.net/11392/2478814.
Texto completoNeuropathic pain is a frequent feature in peripheral neuropathy in particular when small nerve fibers, which convey thermal and nociceptive sensations, are involved. Excruciating burning pain at feet and hand is the most common feature of small fiber neuropathy (SFN) which represents a good model for studying neuropathic pain. Voltage gated sodium channel (VGSCs) genes mutations have been found in rare familial painful disorders and more recently, variants in the same genes have been identified in idiopathic and diabetic painful neuropathies, thus widening the spectrum of genetic pain disorders. This PhD thesis aimed at investigating the risk for neuropathic pain in a well-phenotyped cohort of SFN and diabetic neuropathy patients in order to provide a clinical and genetic characterization of patients. The first section focused on the deep-phenotyping of patients with suspected SFN or neuropathic pain through the development of a database for systematic data collection, integration and sharing among clinicians and researchers. Collected data have been used to conduct two retrospective studies. The first study aimed at addressing the diagnostic accuracy of skin biopsy over time comparing the different normative values for intraepidermal nerve fiber density (IENFD) adopted from 1999 to 2019. This study, comparing skin biopsy results in 439 patients according to different cut-off values, showed a significant improvement of skin biopsy diagnostic specificity after the introduction of the age-and-sex-adjusted normative reference values in the 2010, reporting a reduction of false positive of more than 50% when compared with the cut-off values previously adopted. The second study investigated the circadian dynamics of neuropathic pain intensity scored using the numeric rating scale (PI-NRS) in a cohort of 253 patients with suspected painful SFN. This study revealed a circadian pattern of pain features, showing an increase of NRS scores towards the evening, suggesting a possible role for the intra-day PI-NRS variations as adjunctive outcome measure in clinical trials for analgesic drug in SFN-related neuropathic pain. The second section of the thesis provided a genetic characterization of SFN patients. A candidate-gene analysis has been conducted, looking for rare and low frequency genetic variants in VGSCs genes expected to have a large effect on clinical phenotype and describing their frequency in phenotypically well-defined cohorts of SFN patients. The analysis conducted on 1,015 patients grouped according to etiology and painful phenotype showed a slightly higher frequency of VGSCs variants in painful compared to painless phenotype (13.5% and 9.7%, respectively) but no significant differences between diabetes and idiopathic SFN patients (11.5%). Looking at the variants distribution in VGSCs genes, idiopathic and painful patients showed a significant higher frequency of SCN9A variants whereas diabetes and painless patients had more variants in SCN10A gene. However, concerns have been raised about the pathogenicity of single rare gain-of-function variants, since most of them were classified as VUS (variants of unknown significance). Based on these findings, we adopted a new research approach to investigate the risk of neuropathic pain in our diabetic cohort of 513 patients. The work hypothesis relied on a polygenic architecture of painful neuropathy in which all variants, whether rare or common, might contribute with a small effect size to compose the clinical phenotype. Therefore, we computed a polygenic risk score (PRS) combining the weight of each variant identified in a panel of 107 pain-related genes in diabetic neuropathy patients. The PRS was able to discriminate with sufficient accuracy painful from painless patients with an AUC of 60.3%. This study represented the first application of PRS for addressing the risk of neuropathic pain in diabetic neuropathy, pioneering the use of this tool in this clinical context.
Humble, Stephen R. "Neurosteroids : endogenous analgesics?" Thesis, University of Dundee, 2013. https://discovery.dundee.ac.uk/en/studentTheses/c4659466-cd41-494d-aec6-edcf50e5274b.
Texto completoEvangelista, Afrânio Ferreira. "Avaliação do efeito do transplante de células-tronco mesenquimais derivadas de medula óssea em modelo murino de neuropatia periférica diabética". Centro de Pesquisas Gonçalo Moniz, 2014. https://www.arca.fiocruz.br/handle/icict/9646.
Texto completoApproved for entry into archive by Ana Maria Fiscina Sampaio (fiscina@bahia.fiocruz.br) on 2015-03-06T17:00:06Z (GMT) No. of bitstreams: 1 Afrânio Ferreira Evangelista Avaliação...2014.pdf: 2792913 bytes, checksum: 154973247ed482dbfeac342e4b641d7c (MD5)
Approved for entry into archive by Ana Maria Fiscina Sampaio (fiscina@bahia.fiocruz.br) on 2015-03-06T17:01:18Z (GMT) No. of bitstreams: 1 Afrânio Ferreira Evangelista Avaliação...2014.pdf: 2792913 bytes, checksum: 154973247ed482dbfeac342e4b641d7c (MD5)
Made available in DSpace on 2015-03-06T17:01:18Z (GMT). No. of bitstreams: 1 Afrânio Ferreira Evangelista Avaliação...2014.pdf: 2792913 bytes, checksum: 154973247ed482dbfeac342e4b641d7c (MD5) Previous issue date: 2014
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil
O diabetes é uma doença de alta prevalência que, frequentemente, induz o comprometimento do sistema nervoso periférico. Na neuropatia diabética periférica, os sintomas mais encontrados são os sensitivos, no qual a dor neuropática, condição crônica caracterizada por alodinia e hiperalgesia, é a mais debilitante. Esta, prejudica a qualidade de vida do paciente, sendo muitas vezes não responsiva aos métodos farmacológicos convencionais de tratamento. Diante desse panorama, o desenvolvimento de novas abordagens terapêuticas que possuam ação efetiva neste tipo de dor é de grande relevância. O uso da terapia celular no tratamento de lesões do sistema nervoso tem demonstrado resultados promissores e o potencial terapêutico de células-tronco na neuropatia experimental tem sido proposto. Neste estudo, avaliou-se o efeito de células-tronco mesenquimais derivadas da medula óssea (CMsMO) na neuropatia diabética periférica estabelecida em modelo experimental de diabetes induzido por estreptozotocina (ETZ). Quatro semanas após a indução do modelo por ETZ (80 mg/kg; ip; 3 dias consecutivos), os animais receberam uma administração endovenosa de CMsMO (1 x 106) ou veículo. O tratamento com gabapentina (30 mg/kg; v.o. a cada 12 horas durante seis dias consecutivos) foi usado como padrão ouro. Os limiares nociceptivos térmico e mecânico foram avaliados durante todo o período experimental (90 dias), pelos métodos de hargreaves e von Frey. A avaliação da função motora foi realizada pelo teste de rota-rod. Em diferentes tempos e para todos os grupos experimentais, foram realizadas coletas de segmentos da medula espinal (L4-L5) para dosagem de citocinas por ELISA e segmentos do nervo isquiático foram também coletados para avaliação de alterações morfológicas por microscopia óptica e eletrônica de transmissão. Os dados comportamentais demonstraram que o tratamento com CMsMO reduziu a mecanoalodinia e a hipoalgesia térmica, levando os limiares nociceptivos de animais neuropáticos a níveis similares aos de animais não neuropáticos. Do mesmo modo, a administração de CMsMO normalizou a função motora dos animais neuropáticos. Dados de microscopia mostraram que animais neuropáticos apresentaram atrofia axonal, redução do número de fibras mielínicas e aparente redução do numero de fibras amielínicas no nervo isquiático. Animais neuropáticos tratados com CMsMO tiveram menor ocorrência de atrofia axonal e não apresentaram redução do numero de fibras mielínicas ou amielínicas, em relação aos neuropáticos tratados com salina. Além disso, animais neuropáticos tratados com CMsMO apresentaram menores níveis espinais de IL-1β e TNF-α, e maiores de IL-10 e TGF-β, em relação aos animais neuropáticos não tratados. Esse conjunto de resultados indica que CMsMO produzem efeito antinociceptivo duradouro na neuropatia diabética, seguido de modificações no padrão fisiopatológico da doença, o que aponta a terapia celular como uma interessante alternativa para o controle da neuropatia diabética periférica dolorosa.
Diabetes is a highly prevalent disease which frequently compromises the peripheral nervous system. In peripheral diabetic neuropathy, the most frequent symptoms are sensitive, in which the neuropathic pain, chronic condition characterized by allodynia and hyperalgesia, is the most debilitating. Neuropathic pain affects the quality of patients’ lives, and is often not responsive to pharmacological conventional treatment methods. Against this background, the development of new therapeutic approaches that have an effective action in this type of pain is of great importance. The use of cell therapy in the treatment of lesions in the nervous system has shown promising results and the therapeutic potential of stem cells in experimental neuropathy has been proposed. In this study, we evaluated the effect of mesenchymal stem cells derived from bone marrow (CMsMO) in peripheral diabetic neuropathy established in experimental model of streptozotocin (STZ) induced diabetes in mice. Four weeks after the induction of the model by administration of STZ (80 mg/kg, ip; 3 days) the animals received an CMsMO by intravenous administration (1x106) or vehicle. The treatment with gabapentin (30 mg/kg, orally every 12 hours for six days) was used as the gold standard. The thermal and mechanical nociceptive thresholds were assessed throughout the entire experimental period (90 days), using Hargreaves and von Frey methods, respectively. Motor function evaluation of was conducted using the rotarod test. At different times, were analyzes conducted in spinal cord segments (L4-L5) to determine cytokines profile by ELISA. Sciatic nerve segments were also collected for evaluation of morphological changes by optical and electron transmission microscopy. According to the behavioral data, the CMsMO treatment reduced the mecanoalodinia and the thermal hypoalgesia, leading nociceptive thresholds of neuropathic animals to levels similar to those of non-neuropathic animals. Similarly, CMsMO administration normalized motor function of neuropathic animals. Microscopy data demonstrated that neuropathic animals had axonal atrophy and an apparent decrease of the number of myelinated fibers as well a reduction in the number of unmyelinated fibers in the sciatic nerve, but neuropathic animals treated with CMsMO had a lower incidence of axonal atrophy, showed no decrease in the number of myelinated fibers and no apparent decrease in the amount of unmyelinated fibers in relation to neuropathics treated with saline. Furthermore, neuropathic animals treated with CMsMO presented lower levels of spinal IL-1β and higher levels of TNF-α, and IL-10 and TGF-β compared to neuropathic animals that received saline. These data indicate that CMsMO produces a lasting analgesic effect in diabetic neuropathy, followed by changes in the pathophysiological disease pattern, which indicates cell therapy as an interesting alternative for the control of painful peripheral diabetic neuropathy.
Chan, A. W. "Neuropathic pain in diabetes mellitus". Thesis, Cardiff University, 1991. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.496046.
Texto completoKwiatkowska, Katarzyna Malgorzata <1987>. "Epigenetic Landscape of Pain in Diabetic Neuropathy". Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2021. http://amsdottorato.unibo.it/9577/1/phdThesis_epicPainNet_KKwiatkowska_final.pdf.
Texto completoGeorge, Mary Catherine. "A Comparison of Neuropathic Pain in HIV Disease and Diabetes Mellitus". ScholarWorks, 2017. https://scholarworks.waldenu.edu/dissertations/3989.
Texto completoToniolo, Elaine Flamia. "Caracterização da hemopressina (agonista inverso de receptores canabinóides do tipo 1) na neuropatia diabética experimental". Universidade de São Paulo, 2015. http://www.teses.usp.br/teses/disponiveis/42/42136/tde-09122015-064117/.
Texto completoDiabetic peripheral neuropathy is characterized by hyperalgesia and allodynia. CB1 receptors are primarily responsible for the effect of cannabinoids in nociceptive pathways. Hemopressin (Hp) is an inverse agonist of CB1, which induces antinociception. In this study we investigated the effects of treatment with Hp (2.5 mg / kg for 28 days) on mice subjected to diabetic neuropathy by streptozotocin (STZ - 200 mg/kg). Hp treatement reversed the mechanical hypersensitivity in mice with neuropathy diabetic, and this effect is specific for the treatment of nociception and involves the participation of CB1 receptors, astrocytes and microglia at the spinal level. Hp prevented demyelination of the sciatic nerve in diabetic animals, and assisted in mantaining the levels of NGF. Also, Hp participates in the control of heat sensitivity to thermal stimulus in KO MOR animals and participates in the control of mechanical sensitivity in KO MOR diabetics animals by the increase in CB1-DOR dimerization in the spinal cord. Revealing Hp as a candidate for therapeutic purposes.
DONVITO, GIULIA. "PHARMACOLOGICAL EFFECTS OF PALMITOYLETHANOLAMIDE (PEA) IN DIFFERENT ANIMAL MODELS OF NEUROPATHIC PAIN". Doctoral thesis, Università degli Studi di Milano-Bicocca, 2016. http://hdl.handle.net/10281/101790.
Texto completoPotter, Jeannette Dawn Francesca. "The natural history of neuropathic pain amongst patients with diabetes and patients with cancer". Thesis, King's College London (University of London), 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.415558.
Texto completoLibros sobre el tema "DIABETIC NEUROPATHIC PAIN"
Boulton, Andrew J. M. y Loretta Vileikyte. Managing Neuropathic Pain in the Diabetic Patient. Tarporley: Springer Healthcare Ltd., 2009. http://dx.doi.org/10.1007/978-1-908517-16-6.
Texto completoGaler, Bradley S. Defeat chronic pain now: Groundbreaking strategies for eliminating the pain of arthritis, back and neck conditions, migraines, diabetic neuropathy, and chronic illness. Beverly, MA: Fair Winds Press, 2010.
Buscar texto completoGaler, Bradley S. Defeat chronic pain now!: Groundbreaking strategies for eliminating the pain of arthritis, back and neck conditions, migraines, diabetic neuropathy, and chronic illness. Beverly, MA: Fair Winds Press, 2010.
Buscar texto completoGaler, Bradley S. Defeat chronic pain now: Groundbreaking strategies for eliminating the pain of arthritis, back and neck conditions, migraines, diabetic neuropathy, and chronic illness. Beverly, MA: Fair Winds Press, 2010.
Buscar texto completoNageshwaran, Sathiji, Heather C. Wilson, Anthony Dickenson y David Ledingham. Neuropathic pain. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199664368.003.0005.
Texto completoKhursheed, Faraz y Marc O. Maybauer. Neuropathic Pain. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190271787.003.0012.
Texto completoBoulton, Andrew Jm y Loretta Vileikyte. Managing Neuropathic Pain in the Diabetic Patient. Springer, 2012.
Buscar texto completoVileikyte, Loretta y Andrew JM Boulton. Managing Neuropathic Pain in the Diabetic Patient. Springer Healthcare, 2011.
Buscar texto completoShaibani, Aziz. Numbness. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190661304.003.0023.
Texto completoShaibani, Aziz. Numbness. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199898152.003.0023.
Texto completoCapítulos de libros sobre el tema "DIABETIC NEUROPATHIC PAIN"
Calcutt, Nigel A. y Sandra Chaplan. "Neuropathic Pain Model, Diabetic Neuropathy Model". En Encyclopedia of Pain, 2075–79. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-28753-4_2679.
Texto completoTran, Hai y Daryl I. Smith. "Diabetic Peripheral Neuropathy". En Pathogenesis of Neuropathic Pain, 143–53. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-91455-4_8.
Texto completoBoulton, Andrew J. M. y Loretta Vileikyte. "Management of Neuropathic Pain". En Painful Diabetic Neuropathy in Clinical Practice, 41–58. London: Springer London, 2011. http://dx.doi.org/10.1007/978-0-85729-488-3_4.
Texto completoSawada, Atsushi y Michiaki Yamakage. "Neuropathic Pain Syndrome: Diabetic and Other Neuropathies". En Chronic Pain Management in General and Hospital Practice, 249–60. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-2933-7_14.
Texto completoBoulton, Andrew J. M. y Loretta Vileikyte. "Management of neuropathic pain". En Managing Neuropathic Pain in the Diabetic Patient, 35–48. Tarporley: Springer Healthcare Ltd., 2011. http://dx.doi.org/10.1007/978-1-908517-16-6_4.
Texto completoDobretsov, Maxim, Miroslav Misha Backonja, Dmitry Romanovsky y Joseph R. Stimers. "Animal Models of Diabetic Neuropathic Pain". En Animal Models of Pain, 147–69. Totowa, NJ: Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-880-5_9.
Texto completoBoulton, Andrew J. M. y Loretta Vileikyte. "Introduction to diabetic neuropathies". En Managing Neuropathic Pain in the Diabetic Patient, 1–5. Tarporley: Springer Healthcare Ltd., 2011. http://dx.doi.org/10.1007/978-1-908517-16-6_1.
Texto completoBoulton, Andrew J. M. y Loretta Vileikyte. "Classification and clinical features". En Managing Neuropathic Pain in the Diabetic Patient, 7–19. Tarporley: Springer Healthcare Ltd., 2011. http://dx.doi.org/10.1007/978-1-908517-16-6_2.
Texto completoBoulton, Andrew J. M. y Loretta Vileikyte. "Diagnosis and staging". En Managing Neuropathic Pain in the Diabetic Patient, 21–33. Tarporley: Springer Healthcare Ltd., 2011. http://dx.doi.org/10.1007/978-1-908517-16-6_3.
Texto completoGok Metin, Zehra. "Common Meanings of Living with Diabetic Peripheral Neuropathic Pain from the Perspective of Patients". En Meanings of Pain, 209–31. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-24154-4_11.
Texto completoActas de conferencias sobre el tema "DIABETIC NEUROPATHIC PAIN"
Stella, Isabela de Almeida, Herval Ribeiro Soares Neto, Vanessa de Freiras Moreira, Arthur da Veiga Kalil Coelho, Kássia Braga Canzian, Marcella Canato Toloi, Amanda Freitas Alves y Sephora Sabrina Candido. "Response of neuropathic pain to intravenous immunoglobulin in diabetic amyotrophy: a case report". En XIV Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2023. http://dx.doi.org/10.5327/1516-3180.141s1.686.
Texto completoRizk, Carine, Koby Reid, Khue Tran y Hannah Bass. "PREVENTING THE PROGRESSION OF DIABETIC FOOT ULCERS: ADDRESSING PATIENT COMPLIANCE WITH LOW-COST, BEHAVIOR-MODIFYING WEARABLES". En 2023 Design of Medical Devices Conference. American Society of Mechanical Engineers, 2023. http://dx.doi.org/10.1115/dmd2023-7569.
Texto completoPetersen, Erika, Thomas Stauss, James Scowcroft, Michael Jaasma, Judith White, Shawn Sills, Kasra Amirdelfan et al. "10 kHz SCS Provides Durable Pain Relief and Neurological Improvements for Patients with Painful Diabetic Neuropathy: 24-Month RCT Results (PL4.004)". En 2023 Annual Meeting Abstracts. Lippincott Williams & Wilkins, 2023. http://dx.doi.org/10.1212/wnl.0000000000202464.
Texto completoGulhote, Daniela Alves, Gabriel Santaterra Barros, Mariana Suemi Sukessada, Ana Beatriz Barbosa Piffer, João Fernando Coclet Pio da Silva, Pedro Neves Fortunato, Danilo Takashi Yoshimatsu Ueno, Bruna Franchito Freire y Hilton Mariano da Silva Junior. "Painful ophthalmoplegia due to involvement of cavernous sinus region by malignant neoplasm: report of three cases". En XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.621.
Texto completoBorges, Matheus Araújo, Isabel Cristina Borges de Menezes, Isabela Garcia Bessa, Gabrielly de Souza Correia, Maria Clara Rocha Elias Dib, Rafaela Joy Falcão y Leslivan Ubiratan Moraes. "Sexual dysfunction associated with neurological disorders in men aged 19 to 44 years". En XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.164.
Texto completoKoehler-McNicholas, Sara R., Lori Danzl y Lars Oddsson. "The Effect of a Lower-Limb Sensory Prosthesis on Balance and Gait in People With Peripheral Neuropathy". En 2017 Design of Medical Devices Conference. American Society of Mechanical Engineers, 2017. http://dx.doi.org/10.1115/dmd2017-3466.
Texto completoInformes sobre el tema "DIABETIC NEUROPATHIC PAIN"
Xing, Ying, Hongping Liu, Yifei Wang y Tiancai Wen. Effects of acupuncture on pain in diabetic peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, septiembre de 2022. http://dx.doi.org/10.37766/inplasy2022.9.0019.
Texto completoWang, Liqin, Zhaohong Gao, Xiangru Niu, Meiqi Yuan, Yan Li, Fei Wang, Chuang Guo y Zhen Ren. Acupuncture for diabetic neuropathic pain: protocol for a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, septiembre de 2020. http://dx.doi.org/10.37766/inplasy2020.9.0043.
Texto completoZheng, Ruo-xiang, Jia-wei Xu, Bi-yao Jiang, Wei Tang, Chun-li Lu, Xiao-yang Hu y Jian-ping Liu. Mind-body therapies in traditional Chinese medicine for neuropathic pain: a systematic review of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, abril de 2022. http://dx.doi.org/10.37766/inplasy2022.4.0016.
Texto completoLekhanya, Portia Keabetswe y Kabelo Mokgalaboni. Exploring the effectiveness of vitamin B12 complex and alpha-lipoic acid as a treatment for diabetic neuropathy. Protocol for systematic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, mayo de 2022. http://dx.doi.org/10.37766/inplasy2022.5.0167.
Texto completoLu, Qi, Haili Wang, Weizheng Wang, Yu Gao, Xuefeng Li, Ying Wang, Weiwan Yang y Hongfeng Wang. Efficacy of Electroacupuncture in Painful Diabetic Peripheral Neuropathy: A protocol of systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, noviembre de 2022. http://dx.doi.org/10.37766/inplasy2022.11.0040.
Texto completo